Regeneron (REGN) Reports Dupixent Recommended for EU Approval by the CHMP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Truist Securities on Regeneron Pharma (REGN): 'Buying opportunity'
September 24, 2024 2:18 PM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We spoke with Regeneron (REGN, Buy) mgmt today who noted that they have appealed the court's decision as of last night, and... More
Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)
September 24, 2024 5:30 AM EDTBaird analyst Brian Skorney reiterated a Neutral rating and $940.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "Incrementally negative on legal update. Regeneron's court battles to protect their 2mg Eylea from biosimilar competition has taken a surprising turn as... More
Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)
September 24, 2024 5:28 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $1,292.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We hosted an investor dinner with Len Schleifer, Co-Founder and CEO, and Ryan Crowe, SVP, IR & Strategic Analysis. They emphasized pipeline opportunities stemming from REGN's science-first approach, including: 1) Ph2 proof-of-concept data for the Factor XI antibody in thrombosis by YE, noting validation per genetic data; 2) Ph1 linvoseltamab+Dupixent data in severe food allergy by YE,... More
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
September 23, 2024 4:00 PM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,300.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "With today's denial of Regeneron's motion for a preliminary injunction, it's important that we take a step back and highlight the differences in product formulation across Eylea and select biosimilars as it remains unclear how these differences could contribute to differential rulings in the courtroom. Recall, Regeneron received a permanent injunction vs. Mylan back in June.... More
Truist Securities on Regeneron Pharma (REGN): 'view the pressure on stock as an overreaction'
September 23, 2024 3:40 PM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Regeneron (REGN, Buy) shares were down ~5% (vs. XBI down 2%) in reaction to a Judge denying REGN's preliminary injunction against Amgen's (AMGN, Buy)... More
